The global arthritis pain management market is projected to exhibit considerable growth during the forecast period (2019-2025). The high prevalence of this arthritis disorder, the rapid increase in the R&D activities related to the drug development process for the treatment of this disorder by the key players operating is a major factor anticipated to fuel the arthritis pain management market during the forecast period. Johnson & Johnson Services Inc., F. Hoffman La Roche, Merck & Co. Inc., Sanofi SA, Pfizer Inc., Abbvie, Inc., Allergen PLC, Bayer AG, Amgen Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly and Co., Endo Pharmaceutical, Inc., and so on are the key market players operating in the global arthritis pain management industry.



Get Free Sample Copy @
https://www.omrglobal.com/request-sample/arthritis-pain-management-market



These market players are making a hefty investment in their R&D sector to perform drug development for the launch of new and advanced drugs for the treatment of this disorder. For instance, in February 2020, GlaxoSmithKline Plc received FDA approval fordiclofenac sodium topical gel, 1% (Voltaren Arthritis Pain, GlaxoSmithKline) for temporary relief of arthritis pain. further, in June 2019, Eli Lili & Co. received FDA approval for baricitinib (Olumiant), used to get relief from arthritis pain. Baricitinib is a targeted disease-modifying antirheumatic drug (DMARD) that blocks Janus kinase (JAK), a group of enzymes that enable inflammatory signals to be activated inside a cell.



Browse for Full Report at:
https://www.omrglobal.com/industry-reports/arthritis-pain-management-market



In June 2017, Regeneron Pharmaceuticals, Inc., and Sanofi S.A. received FDA approval for Kevzara (sarilumab) injection to treat adults with moderate to severe rheumatoid arthritis (RA). Kevzara, a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), may be used as monotherapy or in combination with MTX or other DMARDs. This drug is given to the patient who had an inadequate response or intolerance to methotrexate (MTX-IR) drug. Thus, the increasing FDA approval for the drugs and therapy for the treatment of arthritis is anticipated to be a major factor to drive the growth of the global arthritis pain management market.



Current Market Trends Covered in the Market Report.

North America is anticipated to hold a major market share during the forecast period.
The rising awareness among people related to the treatment of arthritis including joint replacement
Partnerships, collaborations, and new product launches – key drivers of competition in the market.


Global Arthritis Pain Management Market Segmentation

By Drug Type
Anti-inflammatory biologics
Disease-Modifying Antirheumatic Drugs (DMARDs)
Non-steroidal anti-inflammatory drugs (NSAIDs)
Corticosteroids
Others

By End-User
Hospitals
Ambulatory Surgical Centres (ASCs)
Others

Global Arthritis Pain Management Market Segmentation by region

North America
United States
Canada

Europe
UK
Germany
Italy
Spain
France
Rest of Europe

Asia-Pacific
China
Japan
India
Rest of the Asia-Pacific

Rest of the World
Middle East & Africa
Latin America



Reasons to Buying From us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.



For More Customized Data, Request for Report Customization @

https://www.omrglobal.com/report-customization/arthritis-pain-management-market



About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.



Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: [email protected]

Contact no: +91 780-304-0404